Novartis: The Buy Thesis Is Back (Rating Upgrade)

Novartis AG ended Q2 on a high note. Despite declining sales of Entresto, the heart failure medicine, the performance of its oncology franchise was remarkably strong. So, sales of Pluvicto, a medication used to treat PSMA-positive metastatic castration-resistant prostate cancer, were $651 million in Q2, up 43.4% year-on-year.

Seeking Alpha • Jul 22, 2026

Novartis Q2 profit up as generic competition mounts

Novartis' second-quarter core operating profit beat ​market expectations on Tuesday, ‌helped by strong sales of cancer and ​multiple sclerosis drugs.

Reuters • Jul 21, 2026

Novartis Silences Generic Fears With Blowout Quarter, Packed Pipeline

Novartis AG (NYSE:NVS) reported better-than-expected second-quarter earnings on Tuesday as strong demand for its priority medicines offset the impact of generic competition, while the Swiss drugmaker reaffirmed its full-year 2026 guidance.

Benzinga • Jul 21, 2026

Novartis Q2 surpasses estimates despite 50% Entresto sales drop

Novartis beat market expectations for second-quarter core operating profit on Tuesday. Lower-than-expected costs helped the Swiss drugmaker offset a sharp decline in sales of its top-selling heart failure drug Entresto.

Invezz • Jul 21, 2026

Novartis CEO Vas Narasimhan says 'no change of plans'

Novartis chief executive ​officer Vas Narasimhan ‌said on Tuesday he plans ​to stick ​around for the Swiss ⁠drugmaker's next ​phase of growth, ​ahead of a series of high-stakes trial ​data expected ​for the company in ‌the ⁠second half of the year.

Reuters • Jul 21, 2026

Novartis Bounds For Buy Point. Why Shares Are On The Rise.

Novartis stock jumped early Tuesday on better-than-expected second-quarter metrics, partially driven by Cosentyx.

Investors Business Daily • Jul 21, 2026

Novartis Q2 Earnings Call Highlights

Novartis NYSE: NVS said it returned to sales growth in the second quarter of 2026, supported by strong gains across priority medicines and launches, while reaffirming its full-year outlook despite continued pressure from U.S. generic erosion tied to Entresto.

MarketBeat • Jul 21, 2026

Novartis Returns to Growth on Sales Momentum From Key Drugs

Second-quarter net sales rose 1% at constant currency as growth from some of its top-selling products offset declines for medicines that lost patent protection.

WSJ • Jul 21, 2026

Novartis CEO on 2Q Profit Beat, Investing in Pipeline

Novartis reported better-than-expected sales and earnings for the second quarter, driven by strong performance from its new cancer medicines which offset declining sales of its former blockbuster drug Entresto. CEO Vas Narasimhan discussed the company's strategic focus on navigating significant patent expiries in the first half of the year, followed by a growth phase in the second half fueled by investments in the pipeline and new product launches.

Bloomberg Markets and Finance • Jul 21, 2026

Novartis AG (NVS) Q2 2026 Earnings Call Transcript

Novartis AG (NVS) Q2 2026 Earnings Call Transcript

Seeking Alpha • Jul 21, 2026